Last Updated on April 1, 2022 by The Health Master
Sun Pharma today announced that one of its wholly-owned subsidiaries has entered into an exclusive patent licensing agreement with H Lundbeck A/S to market and distribute its own version of Vortioxetine in India under the brand name Vortidiftm.
The territory of the licensing agreement will only cover India, the company said in a statement.
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults.
The product is approved in over 80 countries, including the US, EU, Canada and Australia, the statement added.
NPPA extends price revision of Heparin injection, LMO and Oxygen Inhalation
Local manufacturing of 35 APIs started after PLI scheme
Telangana to fill posts of 18 Drug Inspectors, 442 Pharmacists and 15 junior Analysts
Drug recall: Orphenadrine Citrate 100 mg Extended Release Tablets recalled due…
Telangana Minister pitches Hyderabad as Pharma Hub
NPPA updated price lists: Download
NPPA allows price hike of Essential Medicines by more than 10 percent
WHO establishes Global Centre for Traditional Medicine in India
Maharashtra FDA to get 15 new Asstt. Commissioners to combat impending…
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
